580 related articles for article (PubMed ID: 18227491)
21. Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors.
Cox SL
Drugs Today (Barc); 2005 Aug; 41(8):499-508. PubMed ID: 16234873
[TBL] [Abstract][Full Text] [Related]
22. What is the potential role of cannabinoid-1 receptor blockade in glucose and lipid management?
Jensen MD
Am J Med; 2007 Sep; 120(9 Suppl 1):S25-31; discussion S31-2. PubMed ID: 17720358
[TBL] [Abstract][Full Text] [Related]
23. Rimonabant improves obesity but not the overall cardiovascular risk and quality of life; results from CARDIO-REDUSE (CArdiometabolic Risk reDuctIOn by Rimonabant: the Effectiveness in Daily practice and its USE).
Boesten JE; Kaper J; Stoffers HE; Kroon AA; van Schayck OC
Fam Pract; 2012 Oct; 29(5):521-7. PubMed ID: 22389428
[TBL] [Abstract][Full Text] [Related]
24. Cannabinoid-1 receptor antagonists in type-2 diabetes.
Scheen AJ
Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):535-53. PubMed ID: 18054734
[TBL] [Abstract][Full Text] [Related]
25. Potential role of the endocannabinoid receptor antagonist rimonabant in the management of cardiometabolic risk: a narrative review of available data.
Bronander KA; Bloch MJ
Vasc Health Risk Manag; 2007; 3(2):181-90. PubMed ID: 17580728
[TBL] [Abstract][Full Text] [Related]
26. The role of endocannabinoid system blockade in the treatment of the metabolic syndrome.
Kakafika AI; Mikhailidis DP; Karagiannis A; Athyros VG
J Clin Pharmacol; 2007 May; 47(5):642-52. PubMed ID: 17392496
[TBL] [Abstract][Full Text] [Related]
27. Rimonabant for the treatment of overweight and obese people.
Burch J; McKenna C; Palmer S; Norman G; Glanville J; Sculpher M; Woolacott N
Health Technol Assess; 2009 Oct; 13 Suppl 3():13-22. PubMed ID: 19846024
[TBL] [Abstract][Full Text] [Related]
28. Rimonabant: endocannabinoid inhibition for the metabolic syndrome.
Wierzbicki AS
Int J Clin Pract; 2006 Dec; 60(12):1697-706. PubMed ID: 17109677
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of ezetimibe plus orlistat or rimonabant in statin-intolerant nondiabetic overweight/obese patients with dyslipidemia.
Florentin M; Kostapanos MS; Nakou ES; Elisaf M; Liberopoulos EN
J Cardiovasc Pharmacol Ther; 2009 Dec; 14(4):274-82. PubMed ID: 19724023
[TBL] [Abstract][Full Text] [Related]
30. The endocannabinoid system: a promising target for the management of type 2 diabetes.
Scheen AJ
Curr Protein Pept Sci; 2009 Feb; 10(1):56-74. PubMed ID: 19275673
[TBL] [Abstract][Full Text] [Related]
31. Cannabinoid-1 receptor blockade in cardiometabolic risk reduction: safety, tolerability, and therapeutic potential.
Steinberg BA; Cannon CP
Am J Cardiol; 2007 Dec; 100(12A):27P-32P. PubMed ID: 18154743
[TBL] [Abstract][Full Text] [Related]
32. Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.
Florentin M; Liberopoulos EN; Filippatos TD; Kostara C; Tselepis A; Mikhailidis DP; Elisaf M
Expert Opin Pharmacother; 2008 Nov; 9(16):2741-50. PubMed ID: 18937609
[TBL] [Abstract][Full Text] [Related]
33. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders.
Scheen AJ; Paquot N
Best Pract Res Clin Endocrinol Metab; 2009 Feb; 23(1):103-16. PubMed ID: 19285264
[TBL] [Abstract][Full Text] [Related]
34. Rimonabant.
Henness S; Robinson DM; Lyseng-Williamson KA
Drugs; 2006; 66(16):2109-19; discussion 2120-1. PubMed ID: 17112304
[TBL] [Abstract][Full Text] [Related]
35. Rimonabant: new data and emerging experience.
Wright SM; Dikkers C; Aronne LJ
Curr Atheroscler Rep; 2008 Feb; 10(1):71-8. PubMed ID: 18366988
[TBL] [Abstract][Full Text] [Related]
36. [Medication of the month. Rimonabant (Acomplia): first CB1 receptor antagonist of the endocannabinoid system].
Scheen AJ; Van Gaal LF
Rev Med Liege; 2008 Jan; 63(1):50-5. PubMed ID: 18303686
[TBL] [Abstract][Full Text] [Related]
37. Modification of cardiometabolic risk through cannabinoid type-1 receptor antagonism.
Andrikopoulos GK; Tzeis S
Angiology; 2008; 59(2 Suppl):44S-8S. PubMed ID: 18635590
[TBL] [Abstract][Full Text] [Related]
38. Cardiovascular disease under the influence of excess visceral fat.
Després JP
Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
[TBL] [Abstract][Full Text] [Related]
39. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients.
Rosenstock J; Hollander P; Gadde KM; Sun X; Strauss R; Leung A;
Diabetes Care; 2007 Jun; 30(6):1480-6. PubMed ID: 17363756
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials.
Christensen R; Kristensen PK; Bartels EM; Bliddal H; Astrup A
Lancet; 2007 Nov; 370(9600):1706-13. PubMed ID: 18022033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
